Laboratory alterations caused by drugs acting on the nervous system which are part of the List of essential drugs of a northeastern Brazilian municipality
DOI:
https://doi.org/10.30968/rbfhss.2024.151.1020Abstract
Objective: To conduct a survey on the interference of drugs in laboratory tests that are included in the Anatomical Therapeutic Chemical (ATC) N classification (drugs that act on the nervous system), present in the Municipal List of Essential Drugs (REMUME) of the city of Fortaleza, in the state of Ceará. Methods: This is exploratory research. We used as search descriptors the names of the drugs present in the 3rd edition REMUME 2022, the Electronic Bulletin of the National Health Surveillance Agency and UpToDate® databases. Next, the laboratory interferences identified were classified into in vitro and in vivo. Furthermore, in vivo changes were grouped according to the frequency of adverse reactions, based on what is recommended by the Medical Dictionary for Regulatory Activities. Data were compiled and analyzed using Microsoft Office Excel® 2013 software. Results: Of the 50 drugs analyzed, it was observed that only 16% showed no interference in vitro and/or in vivo. The following therapeutic classes exhibited the most in vitro laboratory alterations; anticonvulsants (12%, n=6), followed by antidepressants (6%, n=3). With regard to in vivo alterations, anticonvulsants also were responsible for most of the changes in laboratory testing (22%, n=11), followed by antidepressants (18%, n=9). Biperidene, clobazam, hydroxyzine, nicotine, pramipexole, pyridostigmine, rivastigmine, and rasagiline did not show alterations in vitro or in vivo, according to the literature consulted. The main organic alterations that affects laboratory results observed in this study, involved the hematological system, with reactions of unknown frequency. Conclusion: We found REMUME drugs from the city of Fortaleza-CE, used in clinical situations involving the central nervous system, can cause laboratory changes. Altered laboratory results caused by the drugs and not by the pathology itself may compromise patient’s therapy, generating erroneous medical conducts and consequently iatrogenesis, culminating in long hospital stays and increasing health care costs.
Downloads
References
Ferraro S, Braga F, Panteghini M. Laboratory medicine in the new healthcare environment. Clin Chem Lab Med. 2016;54(4):523-33. DOI: 10.1515/cclm-2015-0803.
van Balveren JA, Verboeket-van de Venne WPHG, Erdem-Eraslan L, et al. Impact of interactions between drugs and laboratory test results on diagnostic test interpretation - a systematic review. Clin Chem Lab Med. 2018;56(12):2004-2009. DOI: 10.1515/cclm-2018-0900.
Ferreira BC, Dos Santos KL, Rudolph SC, et al. Estudo dos medicamentos utilizados pelos pacientes atendidos em laboratorio de análises clínicas e suas interferências em testes laboratoriais: uma revisão de literatura. Rev Eletrônica de Farmácia. 2009;4(1): 33-43. DOI: 10.5216/ref.v6i1.5859
Yao H, Rayburn ER, Shi Q, et al. FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels. Crit Rev Clin Lab Sci. Crit Rev Clin Lab Sci. 2017;54(1):1–17. DOI: 10.1080/10408363.2016.1191425.
Dos Santos SLF, Borges RN, Barros KBNT. Drugs that interfere with the results of laboratory tests: an integrative review of the literature. RBAC. 2018;50(2):105-10. DOI: 10.21877/2448-3877.201800581.
Ferreira AF, Rocha CP, Vieira LM, et al. Alterações hematológicas induzidas por medicamentos convencionais e alternativos. Rev Brasileira de Farmácia. 2013;(94):94-101.
Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020 Sep 1;89(5):283-306. DOI: 10.1159/000506868.
Oliveira JR, Varallo FR, Jirón M, Ferreira IM, Siani-Morello MR, Lopes VD, Pereira LR. Descrição do consumo de psicofármacos na atenção primária à saúde de Ribeirão Preto, São Paulo, Brasil. Cadernos de Saúde Pública. 2021; Jan 11;37:e00060520. DOI: 10.1590/0102-311X00060520.
Katanić J, Stanimirov B, Sekeruš V, Đanić M, Pavlović N, Mikov M, Stankov K. Drug interference with biochemical laboratory tests. Biochemia Medica. 2023; 33(2):020601. DOI: 10.11613/BM.2023.020601.
Boas práticas de farmacovigilância para as Américas [Internet]. Organização Pan-Americana da Saúde (Rede PAHRF Documento Técnico Nº 5). Available from: https://iris.paho.org/handle/10665.2/28455.
Bulário Eletrônico [Internet]. Agência Nacional de Vigilância Sanitária. Available from: https://www.gov.br/anvisa/pt-br/sistemas/bulario-eletronico. Acesso em: 18/05/2023.
Drug Information [Internet]. Uptodate. Available from: https://www.uptodate.com/contents/search.
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf . 1999;20(2):109-17. DOI: 10.2165/00002018-199920020-00002.
Verrotti A, Scaparrotta A, Grosso S, Chiarelli F, Coppola G. Anticonvulsant drugs and hematological disease. Neurological Sciences. 2014 Jul;35:983-93. DOI: 10.1007/s10072-014-1701-0.
Castellanos-Sinco HB, Ramos-Peñafiel CO, Santoyo-Sánchez A, et al. Megaloblastic anaemia: Folic acid and vitamin B12 metabolism. Rev. Medica del Hosp. Gen. de Mex. 2015;78(3):135-143. DOI: 10.1016/j.hgmx.2015.07.001.
Qahtani SAA. Drug-induced megaloblastic, aplastic, and hemolytic anemias: current concepts of pathophysiology and treatment. Int J Clin Exp Med. 2018; 11(6): 5501-5512.
Pagno AR, Gross CB, Gewehr DM, et al. Drug therapy, potential interactions and iatrogenesis as factors related to frailty in the elderly. Rev. bras. geriatr. gerontol. 2018; 21(05): 610-619. DOI: 10.1590/1981-22562018021.180085.
Monitorização da segurança de medicamentos: diretrizes para criação e funcionamento de um Centro de Farmacovigilância [Internet]. Organização Mundial da Saúde. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/seguranca.pdf.
Rocha FL, Hara C, Paprocki J. Doença mental e estigma. Rev Med Minas Gerais. 2015; 25(4): 590-596. DOI: 10.5935/2238-3182.20150127.
Amorim KPC, Garrafa V, De Melo AD, et al. Participantes de ensaios clínicos em oncologia: perfil e aspectos envueltos nas suas decisões.Trab. educ. saúde. 2018; 16(3): 1381-1402. DOI: 10.1590/1981-7746-sol00139.
Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. Antiepileptic drugs: a consideration of clinical and biochemical outcome in patients with epilepsy. International journal of preventive medicine. 2013 May;4(Suppl 2):S330.
Verrotti A, Scaparrotta A, Grosso S, et al. Anticonvulsant drugs and hematological disease. Neurol Sci . 2014;35(7):983-93. DOI: 10.1007/s10072-014-1701-0.
Balda MV, Garay OU, Papale RM, et al.Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012). Int Clin Psychopharmacol . 2015;30(2):109-14. DOI: 10.1097/YIC.0000000000000060.
Padda J, Khalid K, Syam M, Kakani V, Tonpouwo GK, Dhakal R, Padda S, Cooper AC, Jean-Charles G. Association of Anemia With Epilepsy and Antiepileptic Drugs. Cureus. 2021 Nov 7;13(11). DOI: 10.7759/cureus.19334.
Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program. 2017;2017(1):187-193. DOI: 10.1182/asheducation-2017.1.187.
Wolf JM, Wolf LM. Uma revisão sobre a terapêutica anticoagulante oral no manejo da trombose. Rev. Saúde e Biol. 2017;12(1): 66-78.
Vukotić NT, Đorđević J, Pejić S, et al. Arch Toxicol. 2021; 95(3):767–789. DOI: 10.1007/s00204-020-02963-4.
MacAllister SL, Young C, Guzdek A. Molecular cytotoxic mechanisms of chlorpromazine in isolated rat hepatocytes. Can J Physiol Pharmacol . 2013; 91(1): 56-63. DOI: 10.1139/cjpp-2012-0223.
Telles-Correia D, Barbosa A, Cortez-Pinto H, et al. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017 Feb 6; 8(1): 26–38. DOI: 10.4292/wjgpt.v8.i1.26.
Chou AIW, Lu M, Shen WW. Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat. 2014; 10: 1585–1587. DOI: 10.2147/NDT.S67654.
Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015 Jun 1;148(7):1340-52. DOI: 10.1053/j.gastro.2015.03.006.
Das A, Guarda LA, Allen LG. Liver injury associated with quetiapine: an illustrative case report. Journal of clinical psychopharmacology. 2017 Oct 1;37(5):623-5. DOI: 10.1097/JCP.0000000000000749.
Druschky K, Toto S, Bleich S, Baumgärtner J, Engel RR, Grohmann R, Maier HB, Neyazi A, Rudolph YJ, Rüther E, Schwörer H. Severe drug-induced liver injury in patients under treatment with antipsychotic drugs: Data from the AMSP study. The World Journal of Biological Psychiatry. 2021 May 28;22(5):373-86. DOI: 10.1080/15622975.2020.1819565.
Baeza I, de la Serna E, Calvo-Escalona R, Merchan-Naranjo J, Rodriguez-Latorre P, Martínez-Cantarero MC, Andrés P, Alda JA, Munoz-Samons D, Ilzarbe D, Arango C. One-year prospective study of liver function tests in children and adolescents on second-generation antipsychotics: is there a link with metabolic syndrome? Journal of Child and Adolescent Psychopharmacology. 2018 Sep 1;28(7):463-73. DOI: 10.1089/cap.2017.0117.
Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatric Neurology. 2017 Dec 1;77:23-36. DOI: 10.1016/j.pediatrneurol.2017.09.013.
Meseguer ES, Elizalde MU, Borobia AM, Ramírez E. Valproic acid-induced liver injury: A case-control study from a prospective pharmacovigilance program in a tertiary hospital. Journal of Clinical Medicine. 2021 Mar 10;10(6):1153. DOI: 10.3390/jcm10061153.
Sasaki E, Iida A, Oda S, et al. Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. Exp. Toxicol. Pathol. 2016; 68(1): 27-38. DOI: 10.1016/j.etp.2015.09.004.
Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, Karlsen TH, European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. Journal of hepatology. 2019 Jun 1;70(6):1222-61. DOI: 10.1016/j.jhep.2019.02.014.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
